Barclays downgraded Moderna (NASDAQ:MRNA) to Equal Weight from Overweight in a note Tuesday, citing policy risks, a lack of major clinical catalysts, and macroeconomic uncertainties that limit the ...

Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA stock a buy?

Moderna Inc.’s stock erased early losses to gain more than 3% on Friday, after the biotech company posted a ...

The Texas Department of State Health Services canceled its biennial immunization conference amid uncertainty over CDC ...

Happy V-Day! Gorge on heart-shaped chocolate and ponder the implications of RFK Jr. being sworn in as health secretary. Today ...

The vaccine maker posted a loss of $2.91 per share for the quarter, exceeding analysts' estimates of a $2.73 per share loss.

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the decline of its Covid business.

Shares of Moderna, along with other vaccine makers, dropped further this year as lawmakers advanced President Donald Trump's ...

For the fourth time in five months, the Prescription Medicines Code of Practice Authority (PMCPA) has ruled that Moderna brought discredit on the pharma industry. Moderna received the latest ...

Shares of Moderna, Inc. (NASDAQ ... and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella ...

Moreover, Thermo Fisher Scientific’s ongoing and long-term strategic collaboration with Moderna aims to enable dedicated large-scale manufacturing in the US of Spikevax, Moderna’s COVID-19 ...